Is It Time to Call for Improvement in Surgical Techniques for Minimally Invasive Radical Hysterectomy?

Linus Chuang, MD, Pratistha Koirala, MD, PhD, Farr Nezhat, MD

INTRODUCTION

Cervical cancer is the most common pelvic cancer in women worldwide with an annual incidence of 569,847 and 311,365 deaths expected in 2018.1 In the United States, about 13,000 women are diagnosed each year with cervical cancer. Radical hysterectomy (RH) and chemoradiation therapy are both treatment options for women with early-stage cervical cancer. Retrospective studies suggest that RH is as effective as radiation therapy (RT). The only randomized clinical trial comparing these two modalities for women with stage Ib-IIa cervical cancer showed equivalent 5-y overall survival (OS) and disease-free survival (DFS).2 RH as primary treatment is preferred over RT in women who desire the preservation of ovarian function and is associated with fewer long-term sexual dysfunction.3–5

In the recent noninferiority study published in the New England Journal of Medicine by Pedro Ramirez et al., 631 women with stage IA1 (with lymphovascular invasion), IA2, and IB1 cervical cancer were randomized to undergo RH by minimally invasive surgery (MIS) (319 patients) or exploratory laparotomy (RAH) (312 patients) approach; in the MIS group, 84.4% underwent laparoscopic and 15.6% robotic-assisted laparoscopic RH. The RAH group had a slightly more than 10% advantage in 4.5-y DFS over MIS RH (96.5% vs 80.0%). Similarly, a 5% OS advantage at 3 y (99% vs 93.8%) was observed in the RAH group. After the first report of laparoscopic radical hysterectomy with pelvic and paraaortic lymphadenectomy by Nezhat et al. multiple studies have shown that both approaches resulted in equivalent DFS and OS, which is contrary to the results recently reported by Ramirez et al.6,7 Additionally, MIS was associated with benefits such as shorter length of stay, less blood loss, and fewer short- and long-term risks.8–12 Further evaluation of these surgical approaches was reported in seven retrospective studies (Table 1).

In 2014, Nam et al. reported a higher recurrence rate of 8.5% in the MIS RH group as compared with 2.1% in the RAH group. Patients with larger tumor volume had a significantly higher recurrence rate of 42.9% than those with small volume disease (2.5%). However there was no difference in the 3-y DFS between the two approaches in the group with small volume diseases.14 In a subsequent follow-up study performed by the same group, there was no increased risk of recurrence or death associated with laparoscopic radical hysterectomy (LRH). For the patients with tumors >2 cm, the risk for recurrence and survival remained equivalent.9 The equivalent survival rates seen with two different surgical approaches is in agreement with five other studies in which the average tumor size was greater than 2 cm.8,10,13,15,16 Although retrospective in nature, the large number of subjects (total of 1328) included in these multiple previous studies provide compelling evidence for the notion of the safety of LRH or MIS when compared with the RAH. A meta-analysis by Wang et al. found no significant differences in the 5-y OS and DFS following MIS or RAH for early-stage cervical cancer.17 A subsequent meta-analysis by Cao et al. on 2922 patients noted no differences in OS and DFS in patients who underwent LRH vs RAH.11 Meta-analyses have inherent advantages, such as an increased sample size and ability to compare data across multiple trials, as well as limitations, such as their tendency to incorporate biases. Overall, they can be instrumental in verifying the consistency of a finding.18

The current international trial led by Ramirez et al. consists of researchers from multiple sites including China, Korea, Brazil, Colombia, Peru, Italy, and Australia. Although the institutions involved were subjected to trial-related mon-
itoring, audits, institutional review board monitoring, and regulatory inspections by providing direct access to source data/documents, there were limitations in standardization of cancer staging and histopathology. Surgical randomized clinical trials can be limited by the variable technical skills of surgeons involved. An effort was made to standardize surgical techniques by video review, but these videos have not been made available for review. Importantly, there was no centralized review of the pathology specimens. Interobserver discrepancies exist in cervical cancer staging and patient with high-risk diagnoses based on histopathology have poorer outcomes than patients with non-high-risk diagnosis. To limit interobserver bias, a centralized pathology review is an important tool in the execution of clinical trials. This is particularly important because high-quality pathology and laboratory medicine services are often lacking in low- and middle-income countries (LMIC), as defined by the World Bank based on per-capita gross income. Because more than half of the patients included in this trial were accrued from LMICs, it would be important to have a centralized pathology review to determine the accuracy of the pathology specimens. Failure to accurately assess various risk factors may affect the selection of adjuvant therapy for patients with high-risk factors.

Additionally, there was no standardization in preoperative evaluation and imaging to ensure all patients were appropriately staged before being included in the study. Historically, because of a higher incidence in resource-limited LMICs, cervical cancers were staged clinically. Changes to International Federation of Gynecology and Obstetrics cervical cancer staging guidelines, made in 2018, allow for utilization of any preoperative imaging modality including ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography. Although imaging can now contribute to staging, the guidelines acknowledge that imaging modalities are often limited in LMICs and continue to allow clinicians to stage cervical cancers based on the resources that they have available. Because of the lack of standardization of preoperative evaluation in this study, it is possible that the same cancer may have been staged differently in two different countries or institutions, impacting survival outcomes.

In this study, adjuvant therapies were delivered in about 27% of the patients who either underwent open or minimally invasive surgery. There were no differences in the deliveries of chemotherapy or radiotherapy or the days of completion of radiotherapy; however, there was a difference in the recurrence sites between the two approaches. Specifically, vaginal vault recurrences were seen more

| Authors (country)          | Year | Number of cases (MIS vs RAH) | Follow-up (MIS vs RAH in months) | Survival |
|---------------------------|------|------------------------------|---------------------------------|----------|
| Steed (Canada)            | 2004 | 71 vs 205                    | 17 vs 21                        | DFS at 2 years: 94% vs 94% (average tumor size: 2.3 vs 2.6 cm) |
| Nam (Korea)               | 2004 | 47 vs 96                     | 34.5 vs 43.5                    | 86.7% vs 98.9% (DFS at 3 years); no differences if the tumor volume was less than 2 cm |
| Jackson (United Kingdom)  | 2004 | 57 vs 50                     | 52 vs 49                        | OS: 94% vs 96% (average tumor size 1.6 vs 1.7 cm) |
| Li (China)                | 2007 | 90 vs 35                     | 26                              | Mortality rate 10% vs 8% (average tumor size 2.8 vs 2.6 cm) |
| Malzoni (Italy)           | 2009 | 62 vs 65                     | 71.5 vs 52.5                    | DFS: 92.4% vs 96.3% (average tumor size 2.3 vs 2.7 cm) |
| Lee (Korea)               | 2010 | 8 vs 16                      | 78 vs 75                        | DFS at 5 years: 90.5% vs 93.3% (did not address average tumor size) |
| Nam (Korea)               | 2011 | 263 vs 263                   | 91 vs 92                        | DFS at 5 years: 94.4% vs 92.8% (average tumor size 1.8 vs 1.8 cm) |
| Ramirez (Multiple)        | 2005–2011 | 259 vs 232                   | 54 vs 54                        | DFS at 4.5 years: 96.5% vs 80.0% (average tumor size 1.2 vs >1.2 cm) |

MIS, minimally invasive surgery; RAH, exploratory laparotomy; DFS, disease-free survival; OS, overall survival.
often in RAH, whereas all the recurrences in the nonvaginal vault pelvic areas occurred with MIS. Most recurrences in both groups occurred in the pelvis or vaginal vault. This difference was clustered in 14 of 33 recruiting centers; there were within-trial differences in the outcomes; thus, the finding of the study may be heterogenous across the study sites.

Nonetheless, the finding of this study is significant in that a 4-fold increase in the risk of death was observed in women with early cervical cancer who underwent MIS when compared with RAH. The approach of MIS has previously been shown to have equal survival outcomes with improved quality of care for women with endometrial cancers. It thus came as a surprise that this non-inferiority study by Ramirez et al. showed an opposite finding of inferior survival outcomes by a minimally invasive approach for a different gynecologic cancer. The surgical approaches between hysterectomy for endometrial and cervical cancers have many similarities and differences; one fundamental difference is the location of the tumor, with cervical cancer being directly exposed to the abdominal and pelvic cavity during the surgical resection, whereas endometrial cancer is confined within the uterine corpus. Therefore, a surgical approach such as hysterectomy for cervical cancer carries a higher risk of a spread pattern in the pelvis and abdominal cavity, which differs from the typical recurrence of cervical cancer in the vagina and retroperitoneal nodes.6

Although the Ramirez et al. trial was not designed to assess possible mechanisms for poorer survival in the MIS group, they do note the previous studies have associated specific surgical techniques with worse outcomes. These techniques include use of uterine manipulators and the route of vaginal cuff closure. It is unclear how many of the patients in the MIS group had a uterine manipulator used during the surgery. It is possible that the use of uterine manipulator may have led to the disruption and dissemination of the disease. In a large retrospective analysis of 704 patients, a 2.37-fold higher odds of recurrence were observed in patients undergoing MIS with the use of a uterine manipulator for early-stage cervical cancer.29

The method of vaginal cuff closure has been similarly shown to have a survival impact in cervical cancer patients. Kong et al. demonstrated that intracorporeal closure of the colpotomy was associated with higher rates of recurrence than with vaginal approaches. It was hypothesized that high pressure CO2 used in MIS directly led to intraperitoneal spread. During a RH the cervix is not exposed to CO2 until after the colpotomy. An enclosed colpotomy technique ligates the upper portion of the vagina prior to transection of the upper one third of the vagina. By preventing exposure of the cervix to CO2 and to the peritoneal cavity, an enclosed colpotomy may decrease recurrence rates with MIS.31–35

Specific surgical techniques have been associated with worse outcomes in other gynecologic pathology. For example, patients who underwent morcellation for uterine fibroids had a 3-fold higher mortality risk than those who did not have morcellation. This result mirrored that reported in the current 4-fold increased risk in death when surgery was performed with a minimally invasive surgical approach. Our gynecologic community has come a long way through learning from the risk of morcellation of uterine fibroids in the abdominal cavity and has sought to improve surgical techniques and patient outcomes.34

Whereas we applaud the findings from Ramirez et al. in bringing an awareness of the potential risks to women with cervical cancer, it is important to note that many of the studies comparing RAH with MIS accrued data prior to 2010. Over the past decade, robotic surgery techniques have improved, and continue to improve, dramatically. We have an obligation to continue to strive for the innovative surgical approach that is safe and offer superior surgical outcomes for our patients. One of these approaches may be the consideration of the containment of cervical cancer tumor mass similar to what is being researched on for safe morcellation for uterine fibroid.35 The current practice of laparoscopic or robotic radical hysterectomy for cervical cancer or to a lesser extent for endometrial cancer should be used with caution until we find a way to contain cancer that is potentially exposed and may be disseminated to the abdominal cavity.

References:

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (London, England). 1997;350(9077):535–540.

3. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2003;56(4):957–949.

4. Donovan KA, Taliaferro LA, Alvarez EM, Jacobsen PB, Roetzel RG, Wenham RM. Sexual health in women treated for
cervical cancer: Characteristics and correlates. *Gynecol Oncol.* 2007;104(2):428–434.

5. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningssohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. *N Engl J Med.* 1999;340(18):1383–1389.

6. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. *N Engl J Med.* 2018;379(20):1895–1904.

7. Nezhat CR, Burrell MO, Nezhat FR, Benigno BB, Welander CE. Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection. *Am J Obstet Gynecol.* 1992;166(3):864–865.

8. Malzoni M, Tinelli R, Cosentino F, et al. Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer: a prospective randomized study. *Gynecol Oncol.* 2009;112(1):126–135.

9. Nam J-H, Park J-Y, Kim D-Y, Kim J-H, Kim Y-M, Kim Y-T. Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. *Ann Oncol Off J Eur Soc Med Oncol.* 2012;23(4):903–911.

10. Lee EJ, Kang H, Kim DH. A comparative study of laparoscopic radical hysterectomy with radical abdominal hysterectomy for early-stage cervical cancer: a long-term follow-up study. *Eur J Obstet Gynecol Reprod Biol.* 2011;156(1):83–86.

11. Cao T, Feng Y, Huang Q, Wan T, Liu J. Prognostic and safety roles in laparoscopic versus abdominal radical hysterectomy in cervical cancer: a meta-analysis. *J Laparoendosc Adv Surg Tech.* 2015;25(12):990–998.

12. Zakashansky K, Chuang L, Gretz H, Nagarsheth NP, Rahaman J, Nezhat FR. A case-controlled study of total laparoscopic radical hysterectomy with pelvic lymphadenectomy versus radical abdominal hysterectomy in a fellowship training program. *Int J Gynecol Cancer.* 17(5):1075–1082.

13. Steed H, Rosen B, Murphy J, Laframboise S, De Petrillo D, Covens A. A comparison of laparoscopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer. *Gynecol Oncol.* 2004;93(3):588–593.

14. Nam JH, Kim JH, Kim DY, et al. Comparative study of laparoscopico-vaginal hysterectomy and abdominal radical hysterectomy in patients with early cervical cancer. *Gynecol Oncol.* 2004;92(1):277–283.

15. Jackson KS, Das N, Naik R, et al. Laparoscopically assisted radical vaginal hysterectomy vs. radical abdominal hysterectomy for cervical cancer: a match controlled study. *Gynecol Oncol.* 2004;95(3):655–661.

16. Li G, Yan X, Shang H, Wang G, Chen L, Han Y. A comparison of laparoscopic radical hysterectomy and pelvic lymphadenectomy and laparotomy in the treatment of Ib-Ila cervical cancer. *Gynecol Oncol.* 2007;105(1):176–180.

17. Wang Y zhou, Deng L, Xu H cheng, Zhang Y, Liang Z qing. Laparoscopy versus laparotomy for the management of early stage cervical cancer. *BMC Cancer.* 2015;15(1).

18. Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G. Meta-analysis: pitfalls and hints. *Hear Lung Vessel.* 2015;5(4):219–225. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24364016. Accessed September 16, 2019.

19. Nezhat FR, Ananth C V, Vintzileos AM. The two Achilles heels of surgical randomized controlled trials: differences in surgical skills and reporting of average performance. *Am J Obstet Gynecol.* 2019;221(3):230–232.

20. Alfsen GC, Reed W, Abeler VM. Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix. *Gynecol Oncol.* 2003;90(2):282–289.

21. Nagtegaal ID, West NP, van Krieken JHJM, Quirke P. Pathology is a necessary and informative tool in oncology clinical trials. *J Pathol.* 2014;232(2):185–189.

22. Sayed S, Cherniak W, Lawler M, et al. Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions. *Lancet.* 2018;391(10133):1939–1952.

23. WDI. Classifying countries by income. Available at: https://datatopics.worldbank.org/world-development-indicators/stories/the-classification-of-countries-by-income.html. Accessed January 8, 2020.

24. Low and middle income: data. Available at: https://data.worldbank.org/income-level/low-and-middle-income. Accessed January 8, 2020.

25. Sedlis A, Bundy BN, Rotman MZ, Lenzt SS, Maderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. *Gynecol Oncol.* 1999;73(2):177–183.

26. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. *Int J Gynecol Obstet.* 2019;145(1):129–135.

27. Janda M, Gelski V, Brand A, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage 1 endometrial cancer (LACE): a randomised trial. *Lancet Oncol.* 2010;11(8):772–780.

28. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 study. *J Clin Oncol.* 2012;30(7):695–700.

29. Uppal S, Gehrig P, Vetter MH, et al. Recurrence rates in cervical cancer patients treated with abdominal versus minimally
invasive radical hysterectomy: a multi-institutional analysis of 700 cases. *J Clin Oncol.* 2019;37(suppl 15):5504–5504.

30. Kong TW, Chang SJ, Piao X, et al. Patterns of recurrence and survival after abdominal versus laparoscopic/robotic radical hysterectomy in patients with early cervical cancer. *J Obstet Gynaecol Res.* 2016;42(1):77–86.

31. Boyraz G, Karalok A, Basaran D, Turan T. Vaginal closure with EndoGIA to prevent tumor spillage in laparoscopic radical hysterectomy for cervical cancer. *J Minim Invasive Gynecol.* 2019;26(4):602.

32. Chen S, Zheng Y, Tong L, Zhao X, Chen L, Wang Y. Laparoendoscopic single-site radical hysterectomy with vaginal closure and without uterine manipulator for FIGO IB1 cervical cancer. *J Minim Invasive Gynecol.* 2020. [Epub ahead of print].

33. Yuan P, Liu Z, Qi J, Yang X, Hu T, Tan H. Laparoscopic radical hysterectomy with enclosed colpotomy and without the use of uterine manipulator for early-stage cervical cancer. *J Minim Invasive Gynecol.* 2019;26(6):1193–1198.

34. Raspagliesi F, Maltese G, Bogani G, et al. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study. *Gynecol Oncol.* 2017;144(1):90–95.

35. Dotson S, Landa A, Ehrisman J, Secord AA. Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy. *Gynecol Oncol Res Pract.* 2018;5(1).